Last updated: August 27, 2026
The FDA approved Revolution Medicines’ Rasonque (daraxonrasib) on August 26, the first broad RAS targeted medicine in metastatic pancreatic cancer, cutting the risk of death 60% in RASolute 302. Biohaven licensed its Kv7 epilepsy platform to SK Biopharmaceuticals for up to $795 million.
This page covers the Rasonque approval and its data, the Ziihera first line gastric cancer approval, the Biohaven and SK Biopharmaceuticals license, the ended BMS and Cellares agreement, the Summit and Akeso biliary readout, the still unannounced Amylyx closing, and the week’s catalyst tally, with sources.
What did the FDA approve for pancreatic cancer on August 26?
The FDA approved Rasonque (daraxonrasib), Revolution Medicines’ oral RAS(ON) multi selective inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. It is the first approved medicine that targets the broad range of RAS variants.
The label does not require a companion diagnostic, which matters in a tumor where RAS mutations appear in more than 90% of cases. Dosing is 300 mg once daily by mouth. The company cites roughly 55,000 US pancreatic ductal adenocarcinoma diagnoses a year, with about 80% of patients metastatic at diagnosis and a 3% five year survival rate in metastatic disease. The approval came through with Breakthrough Therapy and Orphan Drug designations, under the FDA Commissioner’s National Priority Voucher program, and inside the Project Orbis concurrent international review framework. Reporting from the Associated Press puts the approval about six months ahead of the agency’s target action date and the list price near $39,800 for a month of therapy; the company’s release states neither figure.
How well did daraxonrasib work in the RASolute 302 trial?
In the global Phase 3 RASolute 302 trial, daraxonrasib reduced the risk of death by 60% versus investigator’s choice chemotherapy in the intent to treat population, a hazard ratio of 0.40 with a 95% confidence interval of 0.30 to 0.53 and p below 0.0001. Median time to quality of life deterioration roughly doubled.
| RASolute 302 (ITT) | Rasonque 300 mg daily | Investigator’s choice chemo |
|---|---|---|
| Overall survival | HR 0.40 (95% CI 0.30 to 0.53; p<0.0001), a 60% reduction in risk of death | |
| Median overall survival (per AP reporting) | 13.2 months | 6.7 months |
| Time to QoL deterioration | 5.7 months | 2.6 months (HR 0.60) |
| Most common adverse reactions | Rash 86% (Grade 3: 10%), diarrhea 63% (Grade 3: 6%), stomatitis 57% (Grade 3: 9%); serious adverse reactions in 30% | |
Trial investigator Brian Wolpin of Dana-Farber said daraxonrasib “is well positioned to become a new standard of care” in metastatic pancreatic cancer. The tolerability profile is real but manageable in context: rash in 86% of patients is a high number, yet the comparator is chemotherapy in a disease with a median survival under seven months on standard care.
Why does the timing of the Rasonque approval matter?
Because it is the mirror image of this week’s theme. The week’s scheduled catalyst dates have so far produced zero decisions, while Rasonque, reviewed under the Commissioner’s National Priority Voucher program, arrived ahead of its target date. When a regulator gains from speed, the date is not just met, it is beaten.
We have run a simple sorting rule all week: underwrite the controller of a date, not the calendar. Dates perform when the party controlling them gains from punctuality, which is why exchange controlled dates (IPO pricings, tender windows) ran on schedule while review clocks drifted. The CNPV pathway is the strongest version of that rule on the regulator’s side of the ledger. A voucher program built to showcase speed gives the agency something it rarely has: a reason to be early. The same agency that let Capricor’s August 22 date pass unanswered, that has issued three manufacturing rejections to Xspray, and that placed REGENXBIO’s RGX-121 on hold over surveillance imaging, delivered a first in class pancreatic cancer approval before its own deadline. The variable is not agency speed. It is agency incentive, decision by decision. Holders of the fourth quarter’s dated reviews should sort them the same way.
What are the Ziihera first line gastric cancer approval numbers?
On August 25, the FDA approved Jazz Pharmaceuticals’ Ziihera (zanidatamab-hrii), a HER2 targeted bispecific antibody, in first line HER2 positive advanced gastroesophageal adenocarcinoma, in two regimens: with tislelizumab-jsgr plus chemotherapy, and with chemotherapy alone in IHC 3+ disease.
| HERIZON-GEA-01 | Ziihera arms | Comparator |
|---|---|---|
| Median overall survival | 26.4 months | 19.2 months (28% risk reduction) |
| Median progression free survival | 12.4 months | 8.1 months (35% risk reduction) |
| Notable safety | Diarrhea 83 to 85% (Grade 3 to 4 about 26%; fatal outcomes 1.5% with the triple combination); left ventricular dysfunction 9% with the triple regimen versus 5% dual; infusion related reactions 22 to 24% | |
Jazz’s R&D head Rob Iannone called the result the longest median overall survival reported in a Phase 3 trial in this setting, a gain of more than seven months over the comparator. The molecule originated at Zymeworks; the tislelizumab component is licensed from BeOne Medicines. BioSpace reports Truist forecasting peak sales near $2.5 billion, a figure the company has not confirmed. Two FDA cancer approvals on consecutive days, both on mature survival data, is worth reading next to the agency’s manufacturing caution: the risk budget continues to flow toward biology and away from facilities.
What did SK Biopharmaceuticals pay Biohaven for opakalim?
SK Biopharmaceuticals licensed exclusive global rights to opakalim, Biohaven’s oral once daily Kv7.2/7.3 potassium channel activator for epilepsy, plus the surrounding Kv7 discovery platform, for $400 million in cash ($350 million at closing, $50 million one year later) and up to $395 million in milestones, up to $795 million total.
| Term | Detail |
|---|---|
| Cash | $400M ($350M at closing + $50M one year after closing) |
| Milestones | Up to $395M development and regulatory (portions payable to Knopp Biosciences, the platform’s originator) |
| Royalties | Tiered on US net sales, plus ex US royalties |
| Scope | Global rights to opakalim plus the Kv7 platform and related compounds |
| Stage | Phase 2/3 in refractory focal onset seizures; 1,200+ participants dosed; RISE 3 topline expected end of 2026; second readout 2028; US launch as early as 2029 |
| Close | Subject to antitrust clearance and customary conditions |
For SK Biopharmaceuticals, the Xcopri (cenobamate) company, this is a second US epilepsy franchise bought rather than built, and CEO Donghoon Lee framed it as the move that makes SK “a multi-product company that directly commercializes therapies in the U.S. market.” For Biohaven, whose cash stood at $270.5 million at June 30 per BioSpace after a bruising run of trial failures, it converts a platform into roughly a balance sheet’s worth of firm cash while keeping obesity candidate taldefgrobep alfa, with data due before year end. BHVN closed August 26 at $16.95, up from $14.38 the prior session.
How does the Biohaven deal compare with recent licensing deals?
On cash share, it sits at the certainty end of the curve. Roughly 50% of the total consideration is firm cash, paid for a late stage asset with registrational data due within months. That is the opposite structure from the option style deals that have dominated August.
| Deal (Aug 2026) | Firm cash | Total potential | Cash share | Stage |
|---|---|---|---|---|
| BioMarin / Alesta | $275M | $490M | ~56% | Phase 1/2a |
| Biohaven / SK Biopharmaceuticals | $400M | $795M | ~50% | Phase 2/3, data end 2026 |
| Genentech / Hanmi | $190M | up to $2.3B | ~8% | Phase 1 |
| Haisco / Sentivera | $75.89M cash and equity | over $1.5B | ~5% | Preclinical |
The pattern holds: buyers pay cash for proximity to data and write contingent paper for biology that has not yet spoken. SK is buying a binary with a known expiry, the RISE 3 topline at the end of 2026, and paying up front for the privilege. Note the deal is Korean, like Genentech and Hanmi’s, and sits outside the China political risk frame entirely; no inspection window question, no BINSA exposure. The full framework is in the binary ledger reference table.
Why did Bristol Myers Squibb end its Cellares agreement?
Per BioSpace, BMS terminated its 2024 capacity reservation and supply agreement with Cellares, which BioSpace values at $380 million, because the automated Cell Shuttle system “could not meet the necessary requirements to make commercial Breyanzi,” BMS’s approved CD19 CAR T therapy. Cellares is cutting about 100 jobs effective October 20.
Yesterday we covered those layoffs with the customer unnamed and declined to guess. The name arrived within a day, and it sharpens the lesson. A BMS spokesperson stressed the decision “is specific to Breyanzi and its established, regulatory-approved manufacturing process.” That phrase is the whole story: once a cell therapy’s process is approved, changing it is a regulatory event, and an automation vendor pitching a retrofit is asking the sponsor to reopen its own file. The layoffs come about ten months after Cellares raised $257 million for commercial scale expansion, per BioSpace. Our infrastructure over pipeline thesis has held all month on diversified order books; a capacity business concentrated in one anchor customer carries the same binary risk as the drugs it manufactures. The place automation wins is before approval, when the process is still being designed, not after.
What did Summit and Akeso announce in biliary tract cancer?
Both companies said Phase 3 HARMONi-GI1, run in China in 682 patients with first line biliary tract cancer, met its overall survival primary endpoint at an interim analysis, with ivonescimab plus chemotherapy beating durvalumab plus chemotherapy. Progression free survival and response rate secondaries also hit. No numbers were disclosed.
It is the first Phase 3 ivonescimab readout beyond lung cancer to show a significant survival benefit, and the comparator matters: durvalumab plus chemotherapy is the incumbent immunotherapy standard in this setting. Data go to a congress and a journal, the same no numbers convention now standard from Merck and Moderna to AstraZeneca to Biokin. The US decision that matters for Summit remains the November 14 ivonescimab action date in lung cancer. SMMT closed August 26 at $14.23, up 6.5%.
Did the Amylyx offering ever close?
Not that anyone has announced. As of the evening of August 26, the StockTitan index of Amylyx press releases still shows nothing after the August 19 pricing of the upsized $500.2 million offering, which was expected to close on or about August 21. Three business days past that date, we are now asking directly.
To be precise about what we know and do not know: equity closings routinely settle without a press release, the stock closed August 26 at $37.08, above the $35.50 offer price, and nothing in the tape suggests distress. But the pricing was announced with a wire release, the close was given a date, and that date has passed without a word. In a week we have spent scoring what scheduled dates actually deliver, a company controlled administrative date is supposed to be the reliable kind. The forcing function stands regardless: the underwriters’ 30 day option on 2,113,500 additional shares, roughly $75 million, expires around September 18, and exercised or lapsed it generates disclosure. The question is on the record now; the answer has a deadline.
What happened to the week’s scheduled catalysts?
Through Wednesday evening, the week’s dated events have produced zero decisions and one new date. The only dates that performed were exchange controlled. And the week’s biggest decision, Rasonque, arrived ahead of any date on the calendar.
| Dated event | Status as of Aug 26 evening |
|---|---|
| Capricor PDUFA (was Aug 22) | No decision; new date issued Nov 22 via major amendment |
| Amylyx close (“on or about Aug 21”) | Unannounced; asked in print today; greenshoe forces disclosure by ~Sept 18 |
| Overton confirmation hearing | Still no date (checked Aug 26 evening) |
| Arbutus tender window (opened Aug 24) | On schedule; expires Sept 29 |
| Rasonque approval | Arrived early, under the national priority voucher program |
The tally pays off in tomorrow’s Friday edition with the full ratio. The reference article for the framework is the empty date piece from Monday.
What else moved on August 26?
Vitruvias Therapeutics ceased operations amid a recall of generic thyroid tablets over potential superpotency, per BioSpace. CNBC reports the FDA is weighing two new deputy commissioner posts, one for health and AI and one for drugs, with FDA policy adviser Jared Seehafer floated for the AI role; the agency has not confirmed. Capricor closed at $9.36, up 12.9%, a third straight gain since the November 22 extension with no new company news on its release index as of Wednesday evening. REGENXBIO closed at $9.38, a second session of rebound after last week’s RGX-121 hold. Revolution Medicines closed at $215.44, up 1.9% on approval day.
Frequently asked questions
What is Rasonque (daraxonrasib)?
Rasonque is Revolution Medicines’ oral RAS(ON) multi selective inhibitor, taken 300 mg once daily, approved August 26, 2026 as the first broad RAS targeted medicine for metastatic pancreatic adenocarcinoma after at least one prior systemic therapy.
How much did daraxonrasib improve survival in pancreatic cancer?
In RASolute 302, daraxonrasib reduced the risk of death by 60% versus chemotherapy (hazard ratio 0.40, 95% CI 0.30 to 0.53, p<0.0001). AP reporting puts median overall survival at 13.2 versus 6.7 months.
Does Rasonque require a RAS mutation test?
The approval does not require a companion diagnostic. RAS mutations occur in more than 90% of pancreatic ductal adenocarcinomas, which is part of why a broad RAS targeted agent can be used without one.
What does Rasonque cost?
The Associated Press reports a list price of about $39,800 per month of treatment. Revolution Medicines’ announcement does not state a price, so treat the figure as reported rather than company confirmed.
What is the Commissioner’s National Priority Voucher program?
It is an FDA pathway that grants sharply accelerated review to medicines the agency designates as national priorities. Rasonque was reviewed under it, and AP reporting says the approval landed about six months ahead of the target date.
What did the FDA approve Ziihera for on August 25?
First line HER2 positive advanced gastroesophageal adenocarcinoma: Ziihera with tislelizumab and chemotherapy in IHC 3+ and IHC 2+/ISH+ disease, and Ziihera with chemotherapy alone in IHC 3+ disease.
How long did patients live in the Ziihera gastric cancer trial?
Median overall survival in HERIZON-GEA-01 was 26.4 months on the Ziihera regimens versus 19.2 months on the comparator, a 28% reduction in risk of death and a gain of more than seven months.
What is opakalim?
Opakalim is Biohaven’s oral once daily selective Kv7.2/7.3 potassium channel activator for epilepsy, in Phase 2/3 for refractory focal onset seizures with more than 1,200 participants dosed and RISE 3 topline data expected by the end of 2026.
How much is SK Biopharmaceuticals paying Biohaven?
$400 million in cash ($350 million at closing, $50 million a year later) plus up to $395 million in development and regulatory milestones, up to $795 million total, with tiered royalties, for global rights to opakalim and the Kv7 platform.
Why did BMS terminate the Cellares agreement?
Per BioSpace, BMS said the Cellares Cell Shuttle automated system could not meet requirements for commercial production of Breyanzi, its approved CAR T therapy, and stressed the decision is specific to Breyanzi’s established, regulatory approved process.
Has the Amylyx offering closed?
No closing has been announced as of the evening of August 26. The $500.2 million offering priced August 19 and was expected to close on or about August 21. The underwriters’ option forces disclosure by around September 18.
What did ivonescimab show in biliary tract cancer?
Summit and Akeso said Phase 3 HARMONi-GI1 in China (682 patients, first line) met overall survival versus durvalumab plus chemotherapy at an interim analysis, with no numbers disclosed; data go to a future congress.
When is the FDA decision on ivonescimab in the US?
The FDA action date for ivonescimab in non small cell lung cancer is November 14, 2026. The biliary result is a China trial and does not change the US review clock.
Who might fill the FDA’s new deputy commissioner roles?
CNBC reports the agency is weighing a health and AI post, with FDA senior policy adviser Jared Seehafer floated as a candidate, and a drugs post with no clear frontrunner. The FDA has not confirmed the plan.
Sources
Primary: Revolution Medicines press release, August 26, 2026 (GlobeNewswire); Jazz Pharmaceuticals press release, August 25, 2026, and the FDA’s approval notice for zanidatamab-hrii with tislelizumab-jsgr; Biohaven and SK Biopharmaceuticals joint release, August 26, 2026 (PR Newswire); Amylyx pricing release, August 19, 2026 (Business Wire).
Trade press and market data (attributed): Associated Press via ABC News (Rasonque medians, price, timing); BioSpace, August 26 (Cellares and BMS, Vitruvias, ivonescimab, Ziihera analyst figure, Biohaven context); CNBC, August 25 (FDA deputy commissioner posts); StockTitan press release indexes for AMLX and CAPR checked the evening of August 26; exchange close data as of August 26.
Related coverage
Read yesterday’s report on the Sentivera launch and the IPO window, the Capricor extension and the Hanmi muscle preservation deal, the empty date framework, and the binary ledger tally.
